Analysis of the types of diseases treated by Axitinib (Inlida) and the specific conditions for which it is applicable

Axitinib (Axitinib, trade nameInlyta) is an oral small molecule tyrosine kinase inhibitor (TKI) that mainly acts on vascular endothelial growth factors sub-receptors (VEGFR)1, 2, 3, thereby inhibiting tumor angiogenesis and blocking the growth and spread of tumor cells. Due to its anti-angiogenic properties, axitinib has shown significant efficacy in the treatment of a variety of solid tumors, especially vascular-dependent tumors.

The main clinical indication of axitinib is advanced or metastatic clear cell renal cell carcinoma (RCC). Such patients usually have disease progression after previously receiving first-line therapy (such as sunitinib or sorafenib), and axitinib can be used as a second-line or subsequent treatment option. Studies have shown that axitinib can prolong progression-free survival (PFS), improve tumor control rate, and control side effects, making it an important treatment for advanced RCC.

In addition, axitinib has also shown potential efficacy in some advanced solid tumors, such as vascular-dependent tumors such as thyroid cancer or pancreatic neuroendocrine tumors, but these applications are mostly clinical trials or exploratory studies. For patients, whether axitinib is suitable for use requires a comprehensive assessment of tumor type, stage, previous treatment history, liver and kidney function and other factors to formulate an individualized treatment plan.

In general, axitinib is mainly used for patients with advanced or metastatic clear cell renal cell carcinoma, especially for patients whose disease has progressed after previous treatment with VEGFR inhibitors. By inhibiting angiogenesis, axitinib can effectively control tumor growth, and its oral administration method facilitates long-term treatment for patients. In clinical use, individualized dosage adjustments need to be made based on the patient's specific condition, tumor type and tolerance to ensure treatment safety and maximized efficacy.

Reference materials:https://www.drugs.com/